Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Liabilities and Shareholders Equity (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $621.3 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 28.69% to $621.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 billion through Dec 2025, down 17.45% year-over-year, with the annual reading at $621.3 million for FY2025, 28.69% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $621.3 million at Relay Therapeutics, down from $670.0 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $1.2 billion in Q3 2022, with the low at $621.3 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $863.0 million, with a median of $857.6 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity soared 105.27% in 2021, then dropped 28.69% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $1.0 billion in 2021, then rose by 9.06% to $1.1 billion in 2022, then dropped by 23.26% to $844.0 million in 2023, then increased by 3.24% to $871.3 million in 2024, then decreased by 28.69% to $621.3 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $621.3 million, $670.0 million, and $728.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.